Showing results (1-10 of 121) with videos related to
Sort By:
Pageof 13
Experimental & Molecular Medicine|March 25, 2017
Affibody molecules as engineered protein drugsFredrik Y Frejd, Kyu-Tae KimCurrent Opinion in Biotechnology|July 6, 2011
Non-immunoglobulin based protein scaffoldsJohn Löfblom, Fredrik Y Frejd, Stefan StåhlDrugs in R&D|March 15, 2021
Bispecific Antibody Molecule Inhibits Tumor Cell Proliferation More Efficiently Than the Two-Molecule CombinationAnna-Luisa Volk, Aman Mebrahtu, Bong-Kook Ko, et al.EJNMMI Radiopharmacy and Chemistry|June 25, 2020
Imaging using radiolabelled targeted proteins: radioimmunodetection and beyondJavad Garousi, Anna Orlova, Fredrik Y Frejd, et al.Mabs|August 18, 2016
Targeting HER3 using mono- and bispecific antibodies or alternative scaffoldsMagdalena Malm, Fredrik Y Frejd, Stefan Ståhl, et al.International Journal of Oncology|June 6, 2015
Target-specific cytotoxic effects on HER2-expressing cells by the tripartite fusion toxin ZHER2:2891-ABD-PE38X8, including a targeting affibody molecule and a half-life extension domainHao Liu, Johan Seijsing, Fredrik Y Frejd, et al.European Journal of Nuclear Medicine and Molecular Imaging|December 11, 2008
Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody moleculesVladimir Tolmachev, Eskender Mume, Stefan Sjöberg, et al.Biotechnology and Applied Biochemistry|June 24, 2009
Generation of tumour-necrosis-factor-alpha-specific affibody molecules capable of blocking receptor binding in vitroAndreas Jonsson, Helena Wållberg, Nina Herne, et al.Bioconjugate Chemistry|May 14, 2009
Targeting of epidermal growth factor receptor (EGFR)-expressing tumor cells with sterically stabilized affibody liposomes (SAL)Julia Beuttler, Miriam Rothdiener, Dafne Müller, et al.Scientific Reports|March 25, 2018
In vivo depletion of serum IgG by an affibody molecule binding the neonatal Fc receptorJohan Seijsing, Shengze Yu, Fredrik Y Frejd, et al.Pageof 13